Advocacy intelligence hub — real-time data for patient organizations
NewAmsterdam Pharma — PHASE3
Hasten Biopharmaceutical Co., Ltd. — PHASE3
CRISPR Therapeutics AG — PHASE1
Centre Hospitalier Intercommunal Creteil
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Crestor
(rosuvastatin)Orphan drugstandardiPR Pharmaceuticals, Inc.
12.1 Mechanism of Action CRESTOR is an inhibitor of HMG‑CoA reductase, the rate-limiting enzyme that converts 3‑hydroxy‑3‑methylglutaryl coenzyme A to...
Marina Cuchel, MD, PhD
University of Pennsylvania
Michal Beeri, PHD
Rutgers University
AstraZeneca Crestor Medical Sciences Director, MD
AstraZeneca
Robert D Shamburek, M.D.
National Heart, Lung, and Blood Institute (NHLBI)
Mhy-Lanie Adduru, MD
Predictiv Care, Inc.
Abdulmajeed BS Alzubaidi, MD
Abu Dhabi Health Services Co. -SEHA